TO ASSESS THE EFFICACY AND SAFETY OF PF-06650833, PF-06651600, AND TOFACITINIB ALONE AND IN COMBINATION IN PARTICIPANTS WITH ACTIVE RHEUMATOID ARTHRITIS WITH AN INADEQUATE RESPONSE TO METHOTREXATE

Summary

Dual objectives of increased efficacy compared to currently available SoC RA drugs and maintaining a favourable benefit - risk relationship.

Timeline

Start

2020-07-29

Primary completion

2022-02-07

Completion

2022-02-07

Outcome

Mixed primary results

registry p = 0.0158; Mean Difference (Final Values) -0.35 (90% CI -0.62 to -0.08) NCT04413617 ↗

registry p = 0.3933; Mean Difference (Final Values) -0.04 (90% CI -0.32 to 0.23) NCT04413617 ↗

registry A negative value in change from BL indicates an improvement. NCT04413617 ↗

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Ritlecitinib	Small molecule	100 mg	—
Subject	Tofacitinib	Small molecule	11 mg	—
Subject	ZIMLOVISERTIB	Small molecule	400 mg	—

Indications